169 related articles for article (PubMed ID: 31586600)
1. Efficacy and tolerability of an investigational nitric oxide-releasing topical gel in patients with molluscum contagiosum: A randomized clinical trial.
Hebert AA; Siegfried EC; Durham T; de León EN; Reams T; Messersmith E; Maeda-Chubachi T
J Am Acad Dermatol; 2020 Apr; 82(4):887-894. PubMed ID: 31586600
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Topical Nitric Oxide-Releasing Berdazimer Gel in Patients With Molluscum Contagiosum: A Phase 3 Randomized Clinical Trial.
Browning JC; Enloe C; Cartwright M; Hebert A; Paller AS; Hebert D; Kowalewski EK; Maeda-Chubachi T
JAMA Dermatol; 2022 Aug; 158(8):871-878. PubMed ID: 35830173
[TBL] [Abstract][Full Text] [Related]
3. Berdazimer gel for molluscum contagiosum in patients with atopic dermatitis.
Paller AS; Green LJ; Silverberg N; Stripling S; Cartwright M; Enloe C; Wells N; Kowalewski EK; Maeda-Chubachi T
Pediatr Dermatol; 2024; 41(3):438-444. PubMed ID: 38413239
[TBL] [Abstract][Full Text] [Related]
4. Berdazimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials.
Sugarman JL; Hebert A; Browning JC; Paller AS; Stripling S; Green LJ; Cartwright M; Enloe C; Wells N; Maeda-Chubachi T
J Am Acad Dermatol; 2024 Feb; 90(2):299-308. PubMed ID: 37804936
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2 Controlled Study of SB206, a Topical Nitric Oxide-Releasing Drug for Extragenital Wart Treatment.
Tyring SK; Rosen T; Berman B; Stasko N; Durham T; Maeda-Chubachi T
J Drugs Dermatol; 2018 Oct; 17(10):1100-1105. PubMed ID: 30365591
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
Eichenfield LF; McFalda W; Brabec B; Siegfried E; Kwong P; McBride M; Rieger J; Willson C; Davidson M; Burnett P
JAMA Dermatol; 2020 Dec; 156(12):1315-1323. PubMed ID: 32965495
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Profile, Safety, and Tolerability of Topical Berdazimer Gel, 10.3% in Patients With Molluscum Contagiosum.
Cartwright M; Enloe C; Stripling S; Maeda-Chubachi T
J Drugs Dermatol; 2022 Oct; 21(10):1104-1110. PubMed ID: 36219053
[TBL] [Abstract][Full Text] [Related]
8. Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
Eichenfield LF; Siegfried E; Kwong P; McBride M; Rieger J; Glover D; Willson C; Davidson M; Burnett P; Olivadoti M
Am J Clin Dermatol; 2021 Mar; 22(2):257-265. PubMed ID: 33599960
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of topical nitric oxide-releasing berdazimer gel for molluscum contagiosum clearance: A systematic review and meta-analysis of randomized controlled trials.
Pera Calvi I; R Marques I; Cruz SA; Mesquita YLL; Padrao EMH; Souza RM; Brown A; Caçador DGV; Poppe LM; Lopes Almeida Gomes L
Pediatr Dermatol; 2023; 40(6):1060-1063. PubMed ID: 37721050
[TBL] [Abstract][Full Text] [Related]
10. SB206, a Nitric Oxide-Releasing Topical Medication, Induces the Beginning of the End Sign and Molluscum Clearance.
Maeda-Chubachi T; Hebert D; Messersmith E; Siegfried EC
JID Innov; 2021 Sep; 1(3):100019. PubMed ID: 34909721
[TBL] [Abstract][Full Text] [Related]
11. The Antiviral Effect of Berdazimer Sodium on Molluscum Contagiosum Virus Using a Novel In Vitro Methodology.
Ward BM; Riccio DA; Cartwright M; Maeda-Chubachi T
Viruses; 2023 Nov; 15(12):. PubMed ID: 38140601
[TBL] [Abstract][Full Text] [Related]
12. Topical salicylic acid gel as a treatment for molluscum contagiosum in children.
Leslie KS; Dootson G; Sterling JC
J Dermatolog Treat; 2005; 16(5-6):336-40. PubMed ID: 16428156
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of topical application of 15% and 10% potassium hydroxide for the treatment of Molluscum contagiosum.
Teixidó C; Díez O; Marsal JR; Giner-Soriano M; Pera H; Martinez M; Galindo-Ortego G; Schoenenberger JA; Real J; Cruz I; Morros R
Pediatr Dermatol; 2018 May; 35(3):336-342. PubMed ID: 29479727
[TBL] [Abstract][Full Text] [Related]
14. A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers: Global Impression of Change and Exit Interview Substudy Results.
Browning JC; Cartwright M; Thorla I; Martin SA; Olayinka-Amao O; Maeda-Chubachi T
Am J Clin Dermatol; 2023 Jan; 24(1):119-133. PubMed ID: 36287306
[TBL] [Abstract][Full Text] [Related]
15. Topical Imiquimod is an Effective and Safe Drug for Molluscum Contagiosum in Children.
Badavanis G; Pasmatzi E; Monastirli A; Georgiou S; Tsambaos D
Acta Dermatovenerol Croat; 2017 Jul; 25(2):164-166. PubMed ID: 28871935
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2 Open-Label Study to Evaluate VP-102 for the Treatment of Molluscum Contagiosum.
Niazi S; Brabec B; Anschutz L; Willson C; Davidson M; Burnett P
J Drugs Dermatol; 2021 Jan; 20(1):70-75. PubMed ID: 33400412
[TBL] [Abstract][Full Text] [Related]
17. Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream.
Ormerod AD; White MI; Shah SA; Benjamin N
Br J Dermatol; 1999 Dec; 141(6):1051-3. PubMed ID: 10606851
[TBL] [Abstract][Full Text] [Related]
18. Berdazimer Topical Gel, 10.3%: First Approval.
Keam SJ
Drugs; 2024 Mar; 84(3):363-368. PubMed ID: 38409574
[TBL] [Abstract][Full Text] [Related]
19. New Developing Treatments for Molluscum Contagiosum.
Lacarrubba F; Micali G; Trecarichi AC; Quattrocchi E; Monfrecola G; Verzì AE
Dermatol Ther (Heidelb); 2022 Dec; 12(12):2669-2678. PubMed ID: 36239905
[TBL] [Abstract][Full Text] [Related]
20. Randomized placebo-controlled clinical trial on efficacy and safety of topical 10% Potassium hydroxide for
Giner-Soriano M; Teixidó C; Marsal JR; Díez O; Pera H; Vlacho B; Morros R;
J Dermatolog Treat; 2019 Dec; 30(8):750-756. PubMed ID: 30668179
[No Abstract] [Full Text] [Related]
[Next] [New Search]
